GSTM4

Across TCGA pan-cancer cohorts, GSTM4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GSTM4 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GSTM4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GSTM4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, UCEC, and LUAD are the cancer types where GSTM4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.724	0.237	<.001	46	view →
UCEC	DFS	Median	II,III,IV	0.469	0.944	.002	36	view →
LUAD	DFS	Median	II,III,IV	0.866	0.272	.002	21	view →
HNSC	DFS	Median	All	0.698	1.000	.020	11	view →
LSCC	DFS	Tertile	II,III,IV	0.865	0.553	.032	5	view →
PDAC	OS	Median	IV	0.395	0.937	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GSTM4–CCRCC (DFS)

Open the CCRCC breakdown →